We first evaluated whether HRG overexpression and autocrine transactivation of HER2, independently of HER2 overexpression, might lead to the up-regulation of tumor-associated FASN in an in vitro model of endocrine resistant, luminal B-like breast cancer (Figure 1A, top panel). This evidence concerns the gene ERBB2 and breast cancer.